Companies

A senator has slammed companies for abusing legal professional privilege, after hearing that KPMG has refused to hand over documents in an ASIC investigation into misuse of client information by KPMG auditors.

Saint Gobain-owned CSR has been ordered to hand over monthly performance reports for four business units and its building products division, in a misuse of market power case by insulation distributor Consolidated Energy.

Saint Gobain-owned CSR has been ordered to produce monthly performance reports for four of its business units and its building products division, in a competition case by insulation distributor Consolidated Energy.

Woolworths has told a judge in an underpayments class action where its remediation costs could stretch to $330 million that sending a notice to group members reminding them to keep records would be “premature and potentially misleading”. 

KPMG CEO Andrew Yates has stepped down over his handling of a senior executive's reports of misuse of confidential client information, as the firm hires Big Six firm Allens to investigate the whistleblower's claims.

An ASX statement from budget airline Rex that was optimistic about its 2023 profit prospects should have been corrected by April, ASIC has told a judge, disputing claims that the statement was not a forecast but merely an expression of what the board hoped for. 

Star's former group general counsel has told a judge she should not have to pay a $1.1 million fine for breaching her directors duties because she has suffered “extra-curial detriment” that includes unemployment. 

ASIC is seeking a $1.3 million fine against Star’s former CEO Matthias Bekier and a $1.1 million fine against ex-general counsel Paula Martin for breaching their duties by failing to warn the casino operator's board about money laundering risks. 

NSW workers compensation insurer icare has been hit with a class action on behalf of almost 200,000 claimants whose sensitive data was sent to the wrong insurers and brokers.

AstraZeneca has slammed Pharmacor's defence to claims it infringed a patent for blockbuster diabetes drug Forxiga as a "complete shot in the dark", as the drug maker unsuccessfully fought orders to produce documents from a UK case.